在CML患者中BCR-ABL激酶域突变,来自北印度的第三级护理中心的经验
Akhilesh S1, Arunim Shah2, Ashish Ashish1
1MRU Lab-Dept. of Anatomy, IMS, BHU, Varanasi, India.
Leukemia research reports
|July 22, 2024
概括
很大一部分慢性髓性白血病患者由于BCR-ABL激酶域突变而发展出对伊马替尼的耐药性. 识别这些特定突变对于选择有效的氨酸激酶抑制剂 (TKI) 和管理CML治疗至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 慢性髓性白血病 (CML) 的特征是费城染色体 (Ph) 和BCR::ABL1融合基因.
- 一线氨酸激酶抑制剂 (TKI) 伊马替尼是有效的,但可以产生耐药性,通常是由于BCR::ABL激酶域突变.
- 存在替代性TKI,但灵敏度依赖于突变,需要对个性化CML治疗进行突变分析.
研究的目的:
- 确定和描述BCR::ABL激酶域突变,使北印度CML患者产生意马替尼抗性.
- 为了确定与TKI耐药性相关的特定突变的流行率.
主要方法:
- 使用直接测序分析了329名CML患者的BCR::ABL激酶域.
- 对表现出对伊马替尼治疗耐药性的患者进行了突变分析.
主要成果:
- 在CML患者中,BCR::ABL激酶域突变被检测到20.06% (66/329).
- 在各种领域中发现了突变,ATP结合P-Loop (42.42%) 和直接结合部位 (36.36%) 是最常见的.
- 这些突变赋予了对不同代的技术技术的抵抗力.
结论:
- 很大一部分对伊马替尼布耐药性CML患者具有BCR::ABL激酶域突变.
- 突变分析对于指导选择适当的技术知识和优化CML管理中的治疗策略至关重要.
更多相关视频
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


